Comparison of Rimegepant and Placebo for Pain in IBS

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06221111
Phase
PHASE2
Status
Completed

Conditions

  • Irritable Bowel Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.

Key Dates

Start date
Jun 6, 2024
Status verified
Apr 2026
Primary completion
May 30, 2025
Completion
Jun 3, 2025

Study Design

Enrollment
39 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: rimegepant
    * Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
  • Placebo Comparator: placebo
    Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days

Primary Outcome Measure

Change in Abdominal Pain Scores [ Time Frame: Baseline; Day 28 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Related coverage on Hipa.ai

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies